한빛사논문
- 조회615
Marco Solmi1,2,3,4,5,6, Georgios Seitidis7, Dimitris Mavridis7,8, Christoph U. Correll6,9,10,11, Elena Dragioti12, Synthia Guimond13,14, Lauri Tuominen1,14, Aroldo Dargél1,2,3,15, Andre F. Carvalho16, Michele Fornaro17, Michael Maes18,19,20, Francesco Monaco21,22, Minjin Song23, Jae Il Shin24 and Samuele Cortese5,25,26,27
1Department of Psychiatry, University of Ottawa, Ottawa, ON, Canada.
2On Track: The Champlain First Episode Psychosis Program, Department of Mental Health, The Ottawa Hospital, Ottawa, ON, Canada.
3Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program, University of Ottawa, Ottawa, ON, Canada.
4School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
5Centre for Innovation in Mental Health (CIMH), School of Psychology, Faculty of Environmental and Life Sciences, University of Southampton, Southampton, UK.
6Department of Child and Adolescent Psychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany.
7Department of Primary Education, Evidence Synthesis Methods Team, University of Ioannina, Ioannina, Greece.
8Faculté de Médecine, Paris Descartes University, Sorbonne Paris Cité, Paris, France.
9Department of Psychiatry, Zucker Hillside Hospital, Glen Oaks, NY, USA.
10Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
11Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA.
12Pain and Rehabilitation Centre, and Department of Health, Medicine and Caring Sciences, Linkoping University, SE-581 85 Linkoping, Sweden.
13Department of psychoeducation and psychology, University of Quebec in Outaouais, Gatineau, Canada.
14Department of psychiatry, University of Ottawa, The Royal’s Institute of Mental Health Research, Ottawa, Canada.
15Ottawa Hospital Research Institute (OHRI) Neuroscience Program, University of Ottawa, Ottawa, ON, Canada.
16IMPACT (Innovation in Mental and Physical Health and Clinical Treatment) Strategic Research Centre, School of Medicine, Barwon Health, Deakin University, Geelong, VIC, Australia.
17Section of Psychiatry, Department of Neuroscience, Reproductive Science, and Dentistry, Federico II University of Naples, Naples, Italy.
18University of Electronic Science and Technology of China, Chengdu 611731, China.
19Department of Psychiatry, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, the Thai Red Cross Society, Bangkok, Thailand.
20Department of Psychiatry, and Research Institute, Medical University of Plovdiv, Plovdiv, Bulgaria.
21Department of Mental Health, ASL Salerno, Salerno, Italy.
22European Biomedical Research Institute of Salerno (EBRIS), Salerno, Italy.
23Yonsei University College of Medicine, Seoul, Republic of Korea.
24Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea.
25Clinical and Experimental Sciences (CNS and Psychiatry), Faculty of Medicine, University of Southampton, Southampton, UK.
26Hassenfeld Children’s Hospital at NYU Langone, New York University Child Study Center, New York City, USA. 27Solent NHS Trust, Southampton, UK.
Corresponding authors : Correspondence to Marco Solmi or Jae Il Shin.
Abstract
Schizophrenia substantially contributes to the burden of mental disorders. Schizophrenia's burden and epidemiological estimates in some countries have been published, but updated estimates of prevalence, incidence, and schizophrenia-related disability at the global level are lacking. Here, we present the data from and critically discuss the Global Burden of Diseases, Injuries, and Risk Factors Study data, focusing on temporal changes in schizophrenia's prevalence, incidence, and disability-adjusted life years (DALYs) globally. From 1990 to 2019, schizophrenia raw prevalence (14.2 to 23.6 million), incidence (941,000 to 1.3 million), and DALYs (9.1 to 15.1 million) increased by over 65%, 37%, and 65% respectively, while age-standardized estimates remained stable globally. In countries with high socio-demographic index (SDI), both prevalence and DALYs increased, while in those with low SDI, the age-standardized incidence decreased and DALYs remained stable. The male/female ratio of burden of schizophrenia has remained stable in the overall population over the past 30 years (i.e., M/F = 1.1), yet decreasing from younger to older age groups (raw prevalence in females higher than males after age 65, with males having earlier age of onset, and females longer life expectancy). Results of this work suggest that schizophrenia's raw prevalence, incidence, and burden have been increasing since 1990. Age-adjusted estimates did not reduce. Schizophrenia detection in low SDI countries is suboptimal, and its prevention/treatment in high SDI countries should be improved, considering its increasing prevalence. Schizophrenia sex ratio inverts throughout the lifespan, suggesting different age of onset and survival by sex. However, prevalence and burden estimates for schizophrenia are probably underestimated. GBD does not account for mortality from schizophrenia (and other mental disorders, apart from anorexia nervosa).
논문정보
- Research article
- 2023년 07월 (BRIC 등록일 2023-08-08)
- 국내(교신)+국외 연구진
- 의약학 > 인체시스템의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
